Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$53.99 USD

53.99
2,538,793

+0.23 (0.43%)

Updated Oct 3, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.

Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for COWZ

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for COWZ

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

by Zacks Equity Research

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

by Zacks Equity Research

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

by Zacks Equity Research

Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.

Sundeep Ganoria headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

by Sundeep Ganoria

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

All You Need to Know About Bristol Myers (BMY) Rating Upgrade to Buy

by Zacks Equity Research

Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BMY vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

by Zacks Equity Research

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

by Zacks Equity Research

Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.

Ekta Bagri headshot

Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?

by Ekta Bagri

Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

by Zacks Equity Research

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Ekta Bagri headshot

Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback

by Ekta Bagri

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.

BMY vs. VRTX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.